Mark Reding is an Oncology physician affiliated with University of Minnesota. OpenAlex indexes 118 publications with 2,651 citations (h-index 26); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
420 Delaware St SE
Mmc 480
Minneapolis, MN 554550341
Telephone
612-625-1104Registry record last updated 4 Jan 2013.
Clinical trials
- SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Sponsor: American Thrombosis and Hemostasis Network
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI US SERVICES INC.Program year20251 payment$19,805openpaymentsdata.cms.gov ↗
- HEMA Biologics, LLCProgram year202518 payments$18,164openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year20257 payments$10,730openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2006–2009 per NIH RePORTER. The latest:
- #060201: ADVATE ANTIHEMOPHILIAC FACTOR (RECOMBINANT) PLASMA/ALBUMIN-FREE METHOD
University of Minnesota
FY2009$4,756M01RR000400 - #060201: ADVATE ANTIHEMOPHILIAC FACTOR (RECOMBINANT) PLASMA/ALBUMIN-FREE METHOD
University of Minnesota
FY2008$9,276M01RR000400 - AN OPEN-LABEL STUDY OF THE HEMOSTATIC ACTIVITY, PHARMACOKINETICS AND SAFETY OF O
University of Minnesota
FY2007$5,237M01RR000400
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A
Journal of Thrombosis and Haemostasis
2024 - Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A
New England Journal of Medicine
2023 - Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective
Critical Reviews in Oncology/Hematology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Blazar, MD
University of Minnesota
Jay Cohn, MD
University of Minnesota
Julia Steinberger, MD
University of Minnesota
Charles Herzog, MD
University of Minnesota
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”